The Lancet Commission on prostate cancer: planning for the surge in cases

Nicholas D. James(Royal Marsden NHS Foundation Trust), Liping Xie(First Affiliated Hospital Zhejiang University), Bissan Al‐Lazikani(Institute of Cancer Research), Caroline M. Moore(University College London Hospitals NHS Foundation Trust), Silke Gillessen(Institute of Oncology Research), Larissa Mendes(Royal Marsden Hospital), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Blanca Trujillo(University College London), Paul L. Nguyen(Beth Israel Deaconess Medical Center), Michael J. Morris(Dana-Farber Cancer Institute), Syed Adnan Ali(The Christie Hospital), Felix Y. Feng(University of Michigan), Charles Parker(Royal Marsden NHS Foundation Trust), Archie Macnair(MRC Clinical Trials Unit at UCL), Emily Grist(The University of Adelaide), Derya Tilki(Koç University), Stacy Loeb(Manhattan Physical Medicine and Rehabilitation), Masood Moghul(Royal Marsden NHS Foundation Trust), Anwar R. Padhani(Mount Vernon Cancer Centre), Omolara Fatiregun(Lagos State University), Áine Haran(Royal United Hospital Bath NHS Trust), Vedang Murthy(Homi Bhabha National Institute), James N’Dow(University of Aberdeen), Susan Halabi(Duke Medical Center), Mohamed Jalloh(Cheikh Anta Diop University), Nina Tunariu(Leicester Royal Infirmary), Howard R. Soule(Prostate Cancer Foundation), Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Mark Sculpher(University of York), Éva Compérat(Vienna General Hospital), Michael S. Hofman(Peter MacCallum Cancer Centre), Ian F. Tannock(Princess Margaret Cancer Centre), Freddie Bray(Centre international de recherche sur le cancer), Alicia K. Morgans(Dana-Farber Cancer Institute), Paul Villanti(Movember Foundation), Hannah Rush(University College London), Declan G. Murphy(Peter Doherty Institute), Gerhardt Attard(London Cancer), Brandon A. Mahal(University of Miami), Daniel Herchenhorn(Eastern Cooperative Oncology Group)
The Lancet
April 1, 2024
Cited by 694


Related Papers